JNJ

176.81

-0.44%↓

NVS

122.7

+0.1%↑

ABT

133.07

+0.29%↑

TMO

477.64

+0.38%↑

ISRG

434.46

-1.69%↓

JNJ

176.81

-0.44%↓

NVS

122.7

+0.1%↑

ABT

133.07

+0.29%↑

TMO

477.64

+0.38%↑

ISRG

434.46

-1.69%↓

JNJ

176.81

-0.44%↓

NVS

122.7

+0.1%↑

ABT

133.07

+0.29%↑

TMO

477.64

+0.38%↑

ISRG

434.46

-1.69%↓

JNJ

176.81

-0.44%↓

NVS

122.7

+0.1%↑

ABT

133.07

+0.29%↑

TMO

477.64

+0.38%↑

ISRG

434.46

-1.69%↓

JNJ

176.81

-0.44%↓

NVS

122.7

+0.1%↑

ABT

133.07

+0.29%↑

TMO

477.64

+0.38%↑

ISRG

434.46

-1.69%↓

Search

Sage Therapeutics Inc

Ouvert

SecteurSoins de santé

8.69

Résumé

Variation du prix de l'action

24h

Actuel

Min

8.69

Max

8.69

Dividendes

By Dow Jones

Prochains Résultats

28 oct. 2025

Sentiment de l'Actualité

By Acuity

100%

0%

365 / 375 Classement par Healthcare

Sage Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

31 juil. 2025, 23:56 UTC

Actions en Tendance

Stocks to Watch: Amazon, Bio-Rad, Coinbase, Mercer

31 juil. 2025, 23:48 UTC

Market Talk

Scentre Can Beat Annual Earnings Guidance -- Market Talk

31 juil. 2025, 23:45 UTC

Market Talk

Nikkei May Decline Amid Caution Over Earnings, Domestic Politics -- Market Talk

31 juil. 2025, 23:37 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

31 juil. 2025, 23:37 UTC

Market Talk

Gold Steady as Traders Eye Tariff-Deal Developments -- Market Talk

31 juil. 2025, 23:12 UTC

Résultats

OCBC: Evolving Trade, Monetary Policies, Persistent Geopolitical Tensions Expected to Weigh on Growth Prospects >O39.SG

31 juil. 2025, 23:10 UTC

Résultats

Oversea-Chinese Banking: Declining Interest-Rate Environment Weighed in Net Interest Income >O39.SG

31 juil. 2025, 23:09 UTC

Résultats

Oversea-Chinese Banking 2Q Net Interest Income S$2.28B Vs. S$2.43B >O39.SG

31 juil. 2025, 23:08 UTC

Résultats

Oversea-Chinese Banking 2Q Total Income S$3.55B Vs. S$3.63B >O39.SG

31 juil. 2025, 23:08 UTC

Résultats

Oversea-Chinese Banking 2Q Net S$1.82B Vs. Net S$1.94B >O39.SG

31 juil. 2025, 23:01 UTC

Résultats

Amazon Posts Higher Sales, Profit -- 3rd Update

31 juil. 2025, 22:08 UTC

Market Talk
Résultats

Amazon CEO Impressed by Deals Signed for Project Kuiper -- Market Talk

31 juil. 2025, 22:02 UTC

Market Talk
Résultats

Apple's FY Outlook Shows Sales Growth Won't Last -- Market Talk

31 juil. 2025, 21:57 UTC

Market Talk
Résultats

Amazon CEO Sees Strong Early Demand for Alexa+ -- Market Talk

31 juil. 2025, 21:50 UTC

Résultats

Amazon Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

31 juil. 2025, 21:43 UTC

Résultats

Apple's iPhone Sales Blow Past Estimates as Customers Raced to Beat Tariffs -- 2nd Update

31 juil. 2025, 21:29 UTC

Résultats

Amazon to Invest More in Chips, Data Centers Amid Generative AI Opportunity, CFO Says

31 juil. 2025, 21:26 UTC

Résultats

Apple Expects Revenue to Grow in Mid- to High-Single Digits in Current Quarter, CFO Says

31 juil. 2025, 21:26 UTC

Résultats

MicroStrategy Beats Earnings Estimates. The Stock Rises. -- Barrons.com

31 juil. 2025, 21:22 UTC

Résultats

Amazon Has Impressive Amount of Agreements for Project Kuiper, CEO Says

31 juil. 2025, 21:19 UTC

Résultats

Apple Estimates Tariff Impact to Add $1.1B to Costs in Current Quarter, CEO Says

31 juil. 2025, 21:19 UTC

Résultats

Apple Incurred $800M in Tariff-Related Costs in 2Q, CEO Says

31 juil. 2025, 21:14 UTC

Résultats

Amazon's AWS is Seeing More Demand Than Supply, CEO Says

31 juil. 2025, 21:12 UTC

Résultats

Amazon Saw Record Prime Sign-Ups in 3 Weeks Before Prime Day, CEO Says

31 juil. 2025, 21:10 UTC

Résultats

Amazon Just Getting Started on Automation, Robotics to Boost Efficiency, CEO Says

31 juil. 2025, 21:09 UTC

Résultats

Amazon Delivered to Prime Members at Record Pace in 2Q, CEO Says

31 juil. 2025, 21:09 UTC

Résultats

Amazon CEO Sees Diversity of Sellers as Advantage for Inflation-Weary Consumers

31 juil. 2025, 21:08 UTC

Résultats

Apple iPhone Revenue Performance Driven by Popularity of iPhone 16 Family, CEO Says

31 juil. 2025, 21:08 UTC

Résultats

Amazon CEO Sees Strong Customer Adoption of Perishables Same-Day Delivery Pilot

31 juil. 2025, 21:05 UTC

Résultats

Apple's iPhone Sales Blow Past Estimates as Customers Raced to Beat Tariffs -- Update

Comparaison

Variation de prix

Sage Therapeutics Inc prévision

À Propos Sage Therapeutics Inc

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat